benserazide has been researched along with Anemia in 3 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Benserazide has been used chronically to inhibit amino acid decarboxylase to enhance plasma levels of L-dopa." | 1.42 | Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice. ( Boosalis, MS; Dai, Y; Faller, DV; Li, B; Makala, LH; Nouraie, M; Pace, BS; Perrine, SP; Sangerman, JI; Shen, L; White, E; White, GL; Wolf, RF, 2015) |
| "Renal fibrosis is mediated by the accumulation of myofibroblasts, whereas renal anemia is mediated by the reduced production of fibroblast-derived erythropoietin, a hormone that stimulates erythropoiesis." | 1.37 | Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. ( Asada, M; Asada, N; Fehling, HJ; Fukatsu, A; Kimura, T; Kita, T; Minegishi, N; Nagoshi, N; Nakamura, J; Oguchi, A; Okano, H; Rao, TN; Shibata, S; Suzuki, N; Takase, M; Yamamoto, M; Yamamura, K; Yanagita, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boosalis, MS | 1 |
| Sangerman, JI | 1 |
| White, GL | 1 |
| Wolf, RF | 1 |
| Shen, L | 1 |
| Dai, Y | 1 |
| White, E | 1 |
| Makala, LH | 1 |
| Li, B | 1 |
| Pace, BS | 1 |
| Nouraie, M | 1 |
| Faller, DV | 1 |
| Perrine, SP | 1 |
| Asada, N | 1 |
| Takase, M | 1 |
| Nakamura, J | 1 |
| Oguchi, A | 1 |
| Asada, M | 1 |
| Suzuki, N | 1 |
| Yamamura, K | 1 |
| Nagoshi, N | 1 |
| Shibata, S | 1 |
| Rao, TN | 1 |
| Fehling, HJ | 1 |
| Fukatsu, A | 1 |
| Minegishi, N | 1 |
| Kita, T | 1 |
| Kimura, T | 1 |
| Okano, H | 1 |
| Yamamoto, M | 1 |
| Yanagita, M | 1 |
| Pezzoli, G | 1 |
| Passerini, D | 1 |
| Scarlato, G | 1 |
| Radaelli, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1b Sequential Open Label Dose-Ranging Study of Safety, Pharmacokinetics, and Preliminary Activity of Benserazide in Subjects With Beta Thalassemia Intermedia and Sickle Cell Disease[NCT04432623] | Phase 1/Phase 2 | 36 participants (Anticipated) | Interventional | 2020-10-05 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for benserazide and Anemia
| Article | Year |
|---|---|
Novel Inducers of Fetal Globin Identified through High Throughput Screening (HTS) Are Active In Vivo in Anemic Baboons and Transgenic Mice.
Topics: Anemia; Animals; Benserazide; Drug Evaluation, Preclinical; Erythroid Precursor Cells; Fetal Hemoglo | 2015 |
Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice.
Topics: Anemia; Animals; Benserazide; Cell Differentiation; Cell Lineage; Disease Models, Animal; Drug Combi | 2011 |
Acute non-haemolytic anemia after short administration of L Dopa plus Benserazide.
Topics: Acute Disease; Aged; Anemia; Antiparkinson Agents; Benserazide; Humans; Hydrazines; Levodopa; Male | 1982 |